Although the SPOTLIGHT and GLOW trials defined positivity as moderate-to-strong CLDN18.2 membrane staining in at least 75% of tumor cells [13,14], the scoring cut-offs and methodology used for CLND18 expression evaluation vary in previous publications, reaching values as low as 5% for the number of positive cells used to score a sample as positive and the scoring methods using H-score and IRSs [38,43,44,49,50,51]. Here, CLDN18 is linked to neoplasm.